<p>Akari Therapeutics plc held a special general meeting of shareholders on December 15, 2025. Shareholders approved the exercisability of certain warrants and the issuance of ordinary shares underlying those warrants. Approval was also granted for a share buyback contract for the purchase of all deferred shares. Additionally, authorization was given for the directors to allot shares and grant rights to subscribe for or convert securities into shares up to a specified nominal amount until June 30, 2030. All proposals presented at the meeting were approved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-027969), on December 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

AKTX

<p>Akari Therapeutics plc held a special general meeting on December 15, 2025, where shareholders approved the exercisability of certain warrants, issuance of ordinary shares, a share buyback contract, and authorization for directors to allot shares until June 30, 2030. All proposals were approved.</p>